Viridian Therapeutics: Mixed Bag, Not Eye-Catching Enough (NASDAQ:VRDN)

Introduction

Viridian Therapeutics (NASDAQ:VRDN) is a biopharmaceutical firm committed to creating best-in-class medicines for rare and serious illnesses, specifically where existing treatments fall short. The company’s lead program, VRDN-001, a monoclonal antibody that inhibits insulin-like growth factor-1 receptor (IGF-1R), targets

Read the full article here